Drug Trial Radar · NCT07877597
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Locally advanced colon cancer, particularly T4 disease or colon cancer with bulky nodes, carries a poor prognosis and limited efficacy with neoadjuvant chemotherapy. In our previous small-sample phase II study, PD-1 inhibitor plus CAPOX chemotherapy combined with short-course radiotherapy yielded a marked improvement in the pCR rate compared with neoadjuvant CAPOX alone, though survival outcomes remain under follow-up. This prospective, multicentre, randomised, three-arm phase III study enrolls 480 patients with pMMR/MSS locally advanced high-risk colon cancer. Participants are randomised in a 2:2:1 ratio to three arms: short-course radiotherapy combined with chemotherapy and PD-1 inhibitor (25 Gy in 5 fractions of radiotherapy, followed by 4 cycles of CAPOX plus the PD-1 inhibitor serplulimab); chemotherapy plus PD-1 inhibitor (4 cycles of CAPOX combined with serplulimab); and chemotherapy alone (4 cycles of CAPOX). The primary endpoint is the 3-year event-free survival (EFS) rate. Secondary endpoints include the pCR rate, 5-year overall survival rate (5y OS), R0 resection rate, toxicity, surgical complications and quality of life.
Conditions
- Locally Advanced Colon Cancer
- pMMR
Interventions
short-course radiotherapyRadiation
short-course radiotherapy with 25 Gy in 5 Fractions (25 Gy/5Fx)
SerplulimabDrug
A fixed dose of 300 mg is administered by intravenous infusion on Day 1 (D1), once every 3 weeks (Q3W).
CapOx(Capecitabine+ Oxaliplatin)Drug
Oxaliplatin (130 mg/m²) is administered by intravenous infusion on Day 1. Capecitabine 1000 mg/m² is given orally twice daily (bid) from Day 1 to Day 14, repeated every 3 weeks (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year event-free survivalTime frame: From the date of randomization until the date of first documented disease progression or toxicity during neoadjuvant therapy that prevent surgery, local regional recurrence, distant metastasis, or death, whichever came first, assessed up to 36 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.